Zions Bancorporation National Association UT significantly increased its stake in Vertex Pharmaceuticals, purchasing 9,452 shares to hold a total of 9,638 shares valued at approximately $3.78 million. Vertex Pharmaceuticals reported Q4 EPS of $5.03 and revenues of $3.19 billion, exceeding most forecasts, leading to multiple analyst price target increases and a consensus “Moderate Buy” rating. Despite recent insider selling, institutional investors hold a substantial 90.96% of the stock.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Zions Bancorporation National Association UT Buys 9,452 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Zions Bancorporation National Association UT significantly increased its stake in Vertex Pharmaceuticals, purchasing 9,452 shares to hold a total of 9,638 shares valued at approximately $3.78 million. Vertex Pharmaceuticals reported Q4 EPS of $5.03 and revenues of $3.19 billion, exceeding most forecasts, leading to multiple analyst price target increases and a consensus “Moderate Buy” rating. Despite recent insider selling, institutional investors hold a substantial 90.96% of the stock.